<?xml version="1.0" encoding="UTF-8"?>
<p id="Par94">Johnson &amp; Johnson is working on one that is similar to their platform which was used for the Ebola vaccine; they are using Janssen’s AdVac® adenoviral vector and manufacturing will occur in their PER.C6® cell line technology. This platform is also a candidate for Zika and HIV vaccine. It is at a preclinical stage and is estimated to enter the market next year [
 <xref ref-type="bibr" rid="CR107">107</xref>–
 <xref ref-type="bibr" rid="CR109">109</xref>].
</p>
